Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Actelion Acquires CoTherix For $420 mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

Swiss firm projects that sales of its newly acquired product Ventavis could add roughly $100 mil. in 2007 revenue.

You may also be interested in...



Actelion’s Tracleer Hangs On Against Label-Dampened Letairis

Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.

Actelion’s Tracleer Hangs On Against Label-Dampened Letairis

Edema risk with Gilead competitor probably a class effect or caused by PAH itself, analyst tells "The Pink Sheet" DAILY.

Acusphere Again Delays Imagify NDA, Cites Lengthy Manufacturing Ramp-Up

Firm now targets an early 2008 submission for the cardiac perfusion imaging agent.

Related Content

Topics

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel